N
KNTE

Nuveen’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Nuveen’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-81,967
Closed -$512K – 3330
2023
Q1 		$512K Sell
81,967
-16,739
-17% -$102K ﹤0.01% 2798
2022
Q4 		$602K Sell
98,706
-12,347
-11% -$101K ﹤0.01% 2833
2022
Q3 		$1.33M Sell
111,053
-32
-0% -$419 ﹤0.01% 2609
2022
Q2 		$1.4M Buy
111,085
+19,140
+21% +$178K ﹤0.01% 2621
2022
Q1 		$925K Buy
91,945
+2,069
+2% +$22.8K ﹤0.01% 2842
2021
Q4 		$1.59M Sell
89,876
-5,760
-6% -$121K ﹤0.01% 2679
2021
Q3 		$2.2M Buy
95,636
+37,893
+66% +$825K ﹤0.01% 2624
2021
Q2 		$1.34M Buy
57,743
+8,557
+17% +$218K ﹤0.01% 2885
2021
Q1 		$1.53M Buy
+49,186
New +$1.71M ﹤0.01% 2732

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's KNTE Position: Q2 2023 in Review

Nuveen sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 81,967 shares — an estimated $512K sold.

Nuveen first reported a position in KNTE in Q1 2021 and held it in 9 quarters. The position peaked at $2.2M in Q3 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Nuveen reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Nuveen sold 81,967 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $512K.
  • Nuveen first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Nuveen's Kinnate Biopharma Inc. Common Stock position peaked at $2.2M in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.